Lv2
190 积分 2025-04-16 加入
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
14天前
已完结
HER2-targeted therapies — a role beyond breast cancer
1个月前
已完结
HER2-targeted therapies beyond breast cancer — an update
1个月前
已完结
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
Black cohosh (Cimicifuga racemosa) for menopausal symptoms: A systematic review of its efficacy
3个月前
已完结
The effects of remifemin® on subjective symptoms of menopause
3个月前
已完结
Menopause
3个月前
已关闭
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
3个月前
已完结
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
3个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
4个月前
已完结
皖公网安备34019202002308
